Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil

N/ACitations
Citations of this article
39Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: Severe uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual's quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment. Objective: To review the current status of biologic treatment indications in chronic rhinosinusitis. Methods: The Brazilian Academy of Rhinology brought together different specialists to suggest a course of action, considering its particularities and aspects related to the national reality. Results: Of particular interest for decision making will be the identification of subgroups of patients refractory to pre-existing treatment options and the construction of a strategy that improves their quality of life, with the best cost-benefit ratio. Conclusion: The use of biologics is a valid option for treatment in more severe cases. This strategy must be better understood and improved in the future, with more studies and greater clinical experience.

Cite

CITATION STYLE

APA

Anselmo-Lima, W. T., Tamashiro, E., Romano, F. R., Miyake, M. M., Roithmann, R., Kosugi, E. M., … Valera, F. C. P. (2022, May 1). Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil. Brazilian Journal of Otorhinolaryngology. Elsevier Editora Ltda. https://doi.org/10.1016/j.bjorl.2021.03.003

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free